Last reviewed · How we verify
NCT04680494: SPEMO
Effect of Acute Physical Exercise on Memory
NA trial testing moderate intensity physical exercise in Acute Physical Exercise in 25 participants. Completed in 27 July 2016.
27 July 2016
Quick facts
| Lead sponsor | University of Geneva, Switzerland |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | other |
| Enrollment | 25 |
| Start date | 9 October 2015 |
| Primary completion | 27 July 2016 |
| Estimated completion | 27 July 2016 |
Drugs / interventions tested
- moderate intensity physical exercise
- high intensity physical exercise
- rest
Conditions studied
- Acute Physical Exercise — all drugs for Acute Physical Exercise →
Sponsor
University of Geneva, Switzerland
Who can join
Adults 18 to 38, male only, with Acute Physical Exercise. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An increasing amount of studies show the beneficial effect of regular exercise on cognitive and brain functions and especially in the memory domain. Yet little is known of what happens within an acute bout of exercise and whether it would also yield cognitive effects. The literature clearly shows that molecules such as brain derived neurotrophic factor (BDNF) and endocannabinoids (mainly anandamide, AEA) are heavily involved in neural plasticity mechanisms and increase when we exercise hinting at possible mechanisms underlying memory improvement after exercise. This protocol assesses the effects of acute exercise on associative and motor sequence memory, their underlying neural activations (measured using fMRI) and blood biomarkers (BDNF and AEA). A related aim is to assess the effect of exercise intensity, therefore three exercising conditions (rest, moderate intensity and high intensity) were included. Finally, a 3-month delayed retest visit is also realized to assess effects of acute exercise on long-term memory consolidation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04680494
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Geneva, Switzerland trials
Trials by the same sponsor.
- NCT07461675 — Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resec · Phase 3 · not yet recruiting
- NCT07345858 — Salivary Oxytocin as a Biomarker of Psychedelic Treatment · enrolling by invitation
- NCT07072338 — Promoting Mental and Cognitive Health in Old Age Through Scalable Evidence-based Interventions · NA · not yet recruiting
- NCT06191835 — Implementation of a New Model of Care for Supporting Long-term Medication Adherence (Phase A) · active not recruiting
- NCT05966623 — Assessing the Impact of Vidéo Remote Sign Language Interpreting in Healthcare · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04680494 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Geneva, Switzerland
- Last refreshed: 23 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04680494.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing